8-K current report · filed Aug 5, 2026

RECURSION PHARMACEUTICALS, INC. (RXRX) 8-K Current Report: August 5, 2026

Item 2.02Item 7.01Item EX-99.1RXRX overview

Short answer

RECURSION PHARMACEUTICALS, INC. (RXRX) filed an 8-K current report with the SEC on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 results released for the quarter ended June 30, 2026.

RECURSION PHARMACEUTICALS, INC. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q2 2026 results released for the quarter ended June 30, 2026
  • Press release furnished as Exhibit 99.1, containing the detailed financial results
  • Results announcement provides investors an update on operating performance and financial condition

Item 7.01 · Regulation FD Disclosure

  • Updated corporate presentation released August 5, 2026, providing investors with current company strategy and operating priorities
  • L(earnings) call presentation released August 5, 2026, supplying management’s accompanying investor materials
  • Presentations reference anticipated actions and performance under the Tempus Agreement and Restated Agreement
  • Investors should review Exhibits 99.2 and 99.3 for substantive pipeline, partnership, and financial updates

Item EX-99.1 · Exhibit EX-99.1

  • Q2 revenue $7.7M, down from $19.2M; lower Roche/Genentech recognition reflects completed prior-period project phases
  • Genentech exercised first neuroscience target option, validating Recursion’s platform and initiating a small-molecule discovery program
  • Collaboration economics include up to 40 programs, each with potential milestones exceeding $300M plus tiered royalties up to high single digits
  • Cash $556.8M and runway into early 2028; 2026 cash operating expense guidance reduced to below $375M
  • REC-7735 IND cleared, with Phase 1/2 ZINNIA trial planned for 2H26 and stated mutant selectivity above 100-fold

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other RECURSION PHARMACEUTICALS, INC. 8-K filings

Get the next RXRX 8-K as it lands

Follow RXRX for push alerts, or ask the research agent what this filing means.